Gujarat‐based pharma company Asprius Lifesciences has announced that it has developed treatment for Diabetic Neuropathy, a condition that results in nerve damage in peripheral areas of the body. The company said it has already filed a patent for the Fixed-Dose Combination (FDC) that holds promise in treating peripheral neuropathy, a prevalent condition affecting over 2 per cent of the global population.